Shopping Cart

Your shopping cart is currently empty

GS-9667

Name: GS-9667
Brand: TargetMol
SKU: T27439
Price: 68 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T27439Cas No. 618380-90-8

Alias CVT-3619, CVT 3619

GS-9667, a selective and partial agonist of the A(1) adenosine receptor (AR), represents an effective therapy for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA).

GS-9667

Copy Product Info

😃Good

Purity: 99.96%

Catalog No. T27439Alias CVT-3619, CVT 3619Cas No. 618380-90-8

GS-9667, a selective and partial agonist of the A(1) adenosine receptor (AR), represents an effective therapy for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA).

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$68	In Stock	In Stock
5 mg	$173	In Stock	In Stock
10 mg	$238	In Stock	In Stock
25 mg	$392	In Stock	In Stock
50 mg	$535	In Stock	In Stock
100 mg	$738	In Stock	In Stock
200 mg	$993	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.96%

ee:100%

Appearance:Solid

Color:White to Yellow

Resource Download

COA LCMS CSFC FNMR HNMR ORP

Product Introduction

Bioactivity

Description	GS-9667, a selective and partial agonist of the A(1) adenosine receptor (AR), represents an effective therapy for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA).
In vivo	In the single ascending dose study, healthy, non-obese, and obese subjects received GS-9667 (30-1,800 mg; oral; single dose). In the multiple, ascending dose study, healthy, obese subjects received GS-9667 (600-2,400 mg QD, 1,200 mg BID, or 600 mg QID) for 14 days. Doses of GS-9667 ≥300 mg caused dose-dependent reductions in FFA levels that were reproducible over 14 days without evidence of desensitization or rebound. All doses were well tolerated. GS-9667 was rapidly absorbed and distributed; Steady-state concentrations were achieved within 3-5 days. The A(1) AR partial agonist GS-9667 reduced plasma FFA, exhibited linear kinetics, and was well-tolerated in healthy non-obese and obese subjects.[1]
Synonyms	CVT-3619, CVT 3619

Chemical Properties

Molecular Weight	461.51
Formula	C₂₁H₂₄FN₅O₄S
Cas No.	618380-90-8
Smiles	O[C@H]1[C@H](N2C=3C(N=C2)=C(N[C@H]4[C@H](O)CCC4)N=CN3)O[C@H](CSC5=C(F)C=CC=C5)[C@H]1O
Relative Density.	1.68 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 55 mg/mL (119.17 mM), Sonication is recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.1668 mL	10.8340 mL	21.6680 mL	108.3400 mL
5 mM	0.4334 mL	2.1668 mL	4.3336 mL	21.6680 mL
10 mM	0.2167 mL	1.0834 mL	2.1668 mL	10.8340 mL
20 mM	0.1083 mL	0.5417 mL	1.0834 mL	5.4170 mL
50 mM	0.0433 mL	0.2167 mL	0.4334 mL	2.1668 mL
100 mM	0.0217 mL	0.1083 mL	0.2167 mL	1.0834 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc